Tocagen Inc (TOCA) Set to Announce Quarterly Earnings on Wednesday
Tocagen Inc (NASDAQ:TOCA) is set to issue its quarterly earnings data after the market closes on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.48) per share for the quarter.
Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. On average, analysts expect Tocagen to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Shares of Tocagen Inc (NASDAQ:TOCA) opened at $10.70 on Tuesday. Tocagen Inc has a 1-year low of $8.60 and a 1-year high of $17.95. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.20 and a current ratio of 7.20.
An institutional investor recently bought a new position in Tocagen stock. California State Teachers Retirement System bought a new stake in shares of Tocagen Inc (NASDAQ:TOCA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,900 shares of the company’s stock, valued at approximately $179,000. California State Teachers Retirement System owned about 0.09% of Tocagen as of its most recent SEC filing. Institutional investors own 37.85% of the company’s stock.
TOCA has been the subject of several recent research reports. Stifel Nicolaus restated a “buy” rating and set a $24.00 price objective on shares of Tocagen in a report on Tuesday, July 25th. Zacks Investment Research downgraded Tocagen from a “hold” rating to a “sell” rating in a report on Tuesday, August 15th.
Tocagen Company Profile
Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.
Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.